Monopar Therapeutics MNPR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's retained earnings?
- Monopar Therapeutics (MNPR) reported retained earnings of -$93.4M in Q1 2026.
- How has Monopar Therapeutics's retained earnings changed year-over-year?
- Monopar Therapeutics's retained earnings decreased by 19.1% year-over-year, from -$78.42M to -$93.4M.
- What is the long-term trend for Monopar Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Monopar Therapeutics's retained earnings has grown at a 22.7% compound annual growth rate (CAGR), from -$32.19M to -$89.51M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.